Seror, Raphačle <br/><br/>
Cost-effectiveness of rituximab strategies in rheumatoid arthritis.  [electronic resource] 

 -  Lancet (London, England)  01 2017 
 - 365-366 p.  digital 
<br/><br/> Publication Type: Letter; Comment 
<br/><br/><label>ISSN: </label>1474-547X 
<br/><br/><label>Standard No.: </label>10.1016/S0140-6736(17)30053-3  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antirheumatic Agents<br/>Arthritis, Rheumatoid<br/>Cost-Benefit Analysis<br/>Humans<br/>Rituximab